PDCD1 and colitis: Among these, irAE-induced colitis has been reported in approximately 5.7–9.1% of patients treated with anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibodies and 0.7–1.6% of patients with anti-programmed cell death protein 1 (PD-1) antibodies.